New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population
| Autor: | J O Miquel-Cusachs, Antoni Castells, Xavier Queralt-Moles, Anna Bahí, Lia Oliver, Pau Gilabert, Jordi Guardiola, Virginia Piñol, Manel Ramirez, L. Jesús Garcia-Gil, Joan Saló, Xavier Aldeguer, Mariona Serra-Pagès, Marta Serrano, Joan Amoedo, Marta Malagón, Sara Ramió-Pujol |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology Colorectal cancer Colonoscopy Pathology and Laboratory Medicine Screen test Biochemistry Cohort Studies Feces Medicine and Health Sciences Mass Screening Early Detection of Cancer Rectum -- Cancer education.field_of_study Multidisciplinary medicine.diagnostic_test Immunochemistry Middle Aged Adenomas Bacterial Pathogens Intestins -- Microbiologia Medical Microbiology Occult Blood Cohort Medicine Female Pathogens medicine.symptom Colorectal Neoplasms Algorithms Research Article Cohort study medicine.medical_specialty Science Population Surgical and Invasive Medical Procedures Intestines -- Microbiology Microbiology Sensitivity and Specificity Asymptomatic Digestive System Procedures Signs and Symptoms Diagnostic Medicine Càncer colorectal Internal medicine Cancer Detection and Diagnosis medicine Humans False Positive Reactions education Microbial Pathogens neoplasms Aged Colorectal Cancer Bacteria business.industry Organisms Cancers and Neoplasms Biology and Life Sciences Colonoscòpia medicine.disease digestive system diseases Immunoquímica Spain Lesions False positive rate Clinical Medicine Recte -- Càncer business Biomarkers |
| Zdroj: | PLoS One, 2020, vol. 15, núm. 12, p. e0243158 Articles publicats (D-B) Malagón Rodríguez, Marta Ramió Pujol, Sara Serrano, Marta Amoedo, Joan Oliver, Lia Bahí, Anna Miquel Cusachs, Josep Oriol Ramírez, Manel Queralt Moles, Xavier Gilabert, Pau Saló, Joan Guardiola, Jordi Piñol Sánchez, Virgínia Serra Pagès, Mariona Castells, Antoni Aldeguer i Manté, Xavier Garcia-Gil, L. J. 2020 New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population PLoS One 15 12 e0243158 DUGiDocs – Universitat de Girona instname Dipòsit Digital de la UB Universidad de Barcelona PLoS ONE, Vol 15, Iss 12, p e0243158 (2020) PLoS ONE |
| Popis: | Guidelines recommend routine screening for colorectal cancer (CRC) in asymptomatic adults starting at age 50. The most extensively used noninvasive test for CRC screening is the fecal immunochemical test (FIT), which has an overall sensitivity for CRC of approximately 61.0%-91.0%, which drops to 27.0%-67.0% for advanced adenomas. These figures contain a high false-positive rate and a low positive predictive value. This work aimed to develop a new, noninvasive CRC screening tool based on fecal bacterial markers capable of decreasing FIT false-positive rates in a FIT-positive population. We defined a fecal bacterial signature (RAID-CRC Screen) in a proof-of-concept with 172 FIT-positive individuals and validated the obtained results on an external cohort of 327 FIT-positive subjects. All study participants had joined the national CRC screening program. In the clinical validation of RAID-CRC Screen, a sensitivity of 83.9% and a specificity of 16.3% were obtained for the detection of advanced neoplasm lesions (advanced adenomas and/or CRC). FIT 20 μg/g produced 184 false-positive results. Using RAID-CRC Screen, this value was reduced to 154, thus reducing the false-positive rate by 16.3%. The RAID-CRC Screen test could be implemented in CRC screening programs to allow a significant reduction in the number of colonoscopies performed unnecessarily for FIT-positive participants of CRC screening programs JGG, XA, MSP, MS SRP, JA, LO, MM are employees from GoodGut, a company that has received private and public funding: RTC-2016-5017-1 (Spanish Ministry of Economy, Industry and Competitivity (MINECO)); SNEO-20151529 (Neotec) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|